CAS 206986-87-0|Sodium cholate
| Common Name | Sodium cholate | ||
|---|---|---|---|
| CAS Number | 206986-87-0 | Molecular Weight | 430.553 |
| Density | / | Boiling Point | / |
| Molecular Formula | C24H39NaO5 | Melting Point | / |
| MSDS | USA | Flash Point | / |
Names
| Name | sodium,(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate,hydrate |
|---|---|
| Synonym | More Synonyms |
Sodium cholate BiologicalActivity
| Description | Cholic acid sodium hydrate is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. Cholic acid sodium hydrate facilitates fat absorption and cholesterol excretion. Cholic acid sodium hydrate is orally active[1][2]. |
|---|---|
| Related Catalog | Research Areas >>Metabolic Disease |
| In Vitro | Cholic acid (1 mg/mL, 30 min) competitively binds Na+/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway[1]. |
| In Vivo | Cholic acid (1% (w/w) Cholic acid-supplemented diet; p.o.; 14 days) decreases SHP (small heterodimer partner) protein expression, potentially via the upregulation of miR142-3p. Cholic acid increases CYP2D6 expression and activity[2]. Animal Model: Tg-CYP2D6 adult male mice (8 weeks of age and weighing 20–25 g)[2] Dosage: 1% (w/w) Cholic acid-supplemented diet Administration: Oral, 14 days Result: Decreases SHP expression and increased CYP2D6 activity. |
| References | [1]. Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684. [2]. Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352. |
Chemical & Physical Properties
| Molecular Formula | C24H39NaO5 |
|---|---|
| Molecular Weight | 430.553 |
| Exact Mass | 430.269531 |
| PSA | 100.82000 |
| LogP | 2.11400 |
| InChIKey | QWSPGAWHPXZHEP-RCVKHMDESA-N |
| SMILES | CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C.O.[Na] |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | 24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2918290000 |
Customs
| HS Code | 2918290000 |
|---|---|
| Summary | HS: 2918290000 other carboxylic acids with phenol function but without other oxygen function, their anhydrides, halides, peroxides, peroxyacids and their derivatives Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) VAT:17.0% MFN tariff:6.5% General tariff:30.0% |
Articles9
More Articles| Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly. PLoS ONE 9(8) , e105073, (2014) Royal jelly (RJ) intake lowers serum cholesterol levels in animals and humans, but the active component in RJ that lowers serum cholesterol level and its molecular mechanism are unclear. In this study... | |
| Analysis of extensively washed hair from cocaine users and drug chemists to establish new reporting criteria. J. Anal. Toxicol. 38(9) , 628-36, (2014) Samples from a self-proclaimed cocaine (COC) user, from 19 drug users (postmortem) and from 27 drug chemists were extensively washed and analyzed for COC, benzoylecgonine, norcocaine (NC), cocaethylen... | |
| Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response. Infect. Immun. 82(9) , 3531-41, (2014) Gastroesophageal reflux (GER) frequently occurs in patients with respiratory disease and is particularly prevalent in patients with cystic fibrosis. GER is a condition in which the duodenogastric cont... |
Synonyms
| Sodium (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate |
| Cholan-24-oic acid, 3,7,12-trihydroxy-, sodium salt, (3α,5β,7α,12α)- (1:1) |
| cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3α,5β,7α,8ξ,12α)- |
| (3α,5β,7α,8ξ,12α)-3,7,12-Trihydroxycholan-24-oate de sodium |
| Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3α,5β,7α,12α)- |
| EINECS 206-643-5 |
| Sodium (3α,5β,7α,12α)-3,7,12-trihydroxycholan-24-oate |
| Natrium-(3α,5β,7α,8ξ,12α)-3,7,12-trihydroxycholan-24-oat |
| (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-diméthylhexadécahydro-1H-cyclopenta[a]phénanthrén-17-yl]pentanoate de sodium |
| Natrium-(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoat |
| 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid sodium salt |
| MFCD00064138 |
| cholan-24-oic acid, 3,7,12-trihydroxy-, sodium salt, (3α,5β,7α,8ξ,12α)- (1:1) |
| Sodium cholate |
| Sodium cholate hydrate |
| (3α,5β,7α,12α)-3,7,12-Trihydroxycholan-24-oic acid sodium salt |
| Cholalic acid sodium salt |
| Sodium (3α,5β,7α,8ξ,12α)-3,7,12-trihydroxycholan-24-oate |
